New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 12, 2012
09:05 EDTHZNPHorizon Pharma's RAYOS 5mg reduced morning stiffness in patients with RA
Horizon Pharma announced an additional analysis of data from the pivotal Circadian Administration of Prednisone in Rheumatoid Arthritis-2, or CAPRA- 2, trial demonstrating that patients with active rheumatoid arthritis, or RA, treated with its recently approved RAYOS 5 mg delayed-release tablets who met ACR20, DAS28 and HAQ-DI response criteria had a significantly greater reduction in morning stiffness than patients who didn't meet these criteria. Data were presented during the American College of Rheumatology, or ACR/Association of Rheumatology Health Professionals, or ARHP, Annual Scientific Meeting in Washington, D.C. Results from these analyses demonstrated that morning stiffness duration, morning stiffness severity and pain intensity upon awakening correlated with DAS28 and HAQ-DI in all treatment group analyses. There were stronger absolute correlations seen with morning stiffness severity and pain intensity upon awakening than with morning stiffness duration, whether the treatment groups were analyzed separately or together. Patients who met ACR20, DAS28 and HAQ-DI response criteria had a greater relative reduction in morning stiffness than patients who didn't meet these criteria. There were no safety concerns for RAYOS 5 mg shown in the study beyond those already established for immediate-release prednisone.
News For HZNP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 17, 2015
07:28 EDTHZNPHorizon Pharma price target raised to $38 from $31 at Piper Jaffray
Subscribe for More Information
07:11 EDTHZNPHorizon Pharma Q1 results to beat expectations by wide margin, says Stifel
Stifel believes that Horizon Pharma is benefiting from strong prescription trends, and the firm says its view was bolstered by an update on prescriptions that the company gave earlier this week. Stifel raised its price target on the stock to $40 from $30 and keeps a Buy rating on the shares.
07:03 EDTHZNPHorizon Pharma receives Notice of Allowance from USPTO for Pennsaid
Subscribe for More Information
05:51 EDTHZNPStocks with implied volatility movement; ALU HZNP
Subscribe for More Information
April 16, 2015
09:18 EDTHZNPOn The Fly: Pre-market Movers
Subscribe for More Information
April 15, 2015
18:51 EDTHZNPHorizon Pharma 15.35M share Secondary priced at $28.25
Subscribe for More Information
April 13, 2015
19:18 EDTHZNPOn The Fly: After Hours Movers
Subscribe for More Information
16:45 EDTHZNPHorizon Pharma says Duexis prescriptions up 42% in first 12 weeks of 2015
Subscribe for More Information
16:03 EDTHZNPHorizon Pharma files to sell 12M shares of common stock
Citigroup, Jefferies LLC, Cowen and Company, LLC and Morgan Stanley & Co. LLC are acting as joint book-running managers for this offering.
April 10, 2015
09:16 EDTHZNPOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Quantum (QTM), up 22.2%. ALSO HIGHER: General Electric (GE), up 6.6% after announcing that it will sell most of GE Capital assets for approximately $26.5B... Horizon Pharma (HZNP), up 3.7% after receiving fast track designation for Actimmune... Tekmira Pharmaceuticals (TKMR), up 2.3% after FDA modifies partial clinical hold on Tekmira TKM-Ebola IND... Netflix (NFLX), up 2.9% after being upgraded to Buy from Neutral at Citigroup... Blackstone Mortgage Trust (BXMT), up 3.6% after acquiring $4.6B loan portfolio from GE Capital. LOWER: Citrix Systems (CTXS), down 5.8% after lowering first quarter guidance... Uniqure (QURE), down 2.4% after 3M share Secondary priced at $29.50... FIS (FIS), down 2.5% after lowering first quarter guidance... Golub Capital (GBDC), down 2.3% after 3.5M share Spot Secondary priced at $17.42.
07:02 EDTHZNPHorizon Pharma receives FDA fast track designation for Actimmune
Horizon Pharma announced the FDA granted Fast Track designation for Actimmune in the treatment of Friedreich's ataxia, or FA, a degenerative neuro-muscular disorder. The company submitted the Investigational New Drug, or IND, application for Actimmune in the treatment of FA in February and announced plans to begin a Phase 3 study in the second quarter in collaboration with the Friedreich's Ataxia Research Alliance, or FARA, and a sub-set of FARA's Collaborative Clinical Research Network, or CCRN, study centers in FA.
April 7, 2015
07:15 EDTHZNPHorizon Pharma management to meet with UBS
Meetings to be held in Austin/Houston on April 7 hosted by UBS.
April 6, 2015
07:25 EDTHZNPHorizon Pharma management to meet with UBS
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use